Exciting news! Eli Lilly's Alzheimer's drug, donanemab, has shown promising results in late-stage clinical trials, limiting cognitive decline by approximately 35%. The antibody-based treatment demonstrated the ability to slow disease progression in its early stages. Eli Lilly plans to seek FDA approval for this groundbreaking medication. Earlier this month, a similar drug, lecanemab, received full approval. A significant breakthrough in the fight against Alzheimer's disease! 🎉 #Alzheimers #MedicalAdvancements